We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
-15.65%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$146M
AUM Growth
–
Cap. Flow
+$169M
Cap. Flow %
116.05%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$86.8M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$76.1M
3
CYTK icon
Cytokinetics
CYTK
+$6.42M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$151K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$78.1M 53.45%
+2,111,111
New +$76.1M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$62.4M 42.73%
+4,373,178
New +$86.8M
CYTK icon
3
Cytokinetics
CYTK
$10.8B
$5.53M 3.79%
+875,656
New +$6.42M
VIRX
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$54K 0.04%
+3,700
New +$151K

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2018 Portfolio in Review

Q4 2018 is the first quarter with a 13F filing on record for RP Management, which disclosed 4 positions worth $146M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Immunomedics Inc: 4,373,178 shares worth $62.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • RP Management's largest Q4 2018 buy was Immunomedics Inc: 4,373,178 shares worth $62.4M.
  • RP Management's ten largest holdings make up 100% of its $146M portfolio in Q4 2018.
  • RP Management disclosed 4 positions in Q4 2018, its first 13F filing on record.

Based on RP Management's 13F filing for Q4 2018, filed 14 Feb 2019.